Since 1998, she has been working at Medical Oncology of Sun Yat-sen University Cancer Center and Good Clinical Practice (GCP) Center for New Anticancer Drugs. She is familiar with theories and techniques of molecular biology, capable of conducting experiment in cell biology, flow cytometry experiment and Western Blot; she has also mastered pharmacology experimental theories and techniques of pharmacology for anticancer drugs, and is able to inoculate tumor-bearing nude mice to test the anti-tumor efficacy of anticancer drugs. She has published more than 10 papers, and has led several research projects.

What is more, she has mastered biopharmaceutical analysis of drugs, proficient in operating atomic absorption spectroscopy instrument, high-performance liquid chromatography instrument, ultraviolet–visible spectrophotometer, microplate reader, RT-PCR instrument, and etc. She is familiar with national guidelines for GCP for trials on pharmaceutical products, including those for pharmacokinetic experiment, capable of establishing pharmacokinetic analysis methods and determining drug concentration; she can write plans and reports for pharmacokinetic experiments in Phase I/II/III clinical trials, and conduct preliminary analysis on pharmacokinetic-pharmacodynamic relationship, and the interaction of drugs.

Since 1998, she has led clinical pharmacokinetic study on several domestic and foreign Category I new drugs. Pharmacokinetic study of Phase I clinical trial of domestic drugs includes E10A (preparation for endostatin gene), ATV-TK/GCV, vinflunine, dicycloplatin, combretastatin, puquitinib mesylate, SM03 (CD22 monoclonal antibody), and fluorapacin; pharmacokinetic study of Phase I clinical trial of foreign drugs: ZD6474 and capxol; pharmacokinetic study of Phase III clinical trial: epothilone and etc.

Appointed as the chief physician of Sun Yat-sen University Cancer Prevention and Treatment Center, and served as the deputy director of the Department of Clinical Research, the head of the Stage I ward, the attending professor, and the supervisor of doctoral students since 2017.

Since the establishment of Phase I Ward of Cancer Prevention and Treatment Center in 2014, responsible for the daily medical management of Phase I Ward of New Anti-tumor Drugs and Clinical Research Day Ward in Yuexiu Hospital. During the 14th Five-Year Plan period, the percentage of First in Class new drug projects in our Phase I ward ranked the first in Chinese oncology hospitals, and our Phase I ward has developed into the most influential Phase I clinical research ward for new antitumor drugs in China.

Academically, made certain scientific achievements in clinical, translational and basic research on immuno/targeted/chemotherapeutic drugs for lung/nasopharyngeal cancer, and published 158 papers in international journals, of which 67 papers were published as first (including co-first) or corresponding (including co-corresponding) authors in the well-known journals, such as Lancet Oncology, Signal Transduction and Targeted Therapy, Cancer Cell, J Hematology & Oncology, J Thoracic Oncology, J Immunotherapy of Cancer, Cancer Letters and so on. Responsible for more than 50 international and domestic phase I clinical studies, and led a phase III clinical study of a multicenter randomized controlled dual-targeted combination therapy for lung cancer. Currently, as the first person in charge, presided three top-level projects of National Natural Science Foundation of China (NSFC), two projects of Guangdong Provincial Natural Science Foundation (GDNSF), one project of Guangzhou Key Research and Development Program (GZKRP), one project of Sun Yat-sen University (SYSU) Clinical Medical Research Program (CMRP), and one project of Heathcote-Junshi Tumor Immunology Research Fund (JRF). Many research results have been presented at the American Society of Clinical Oncology (ASCO) and the European Society of Medical Oncology (ESMO-Asia), such as poster discussions and oral presentations.

In order to strengthen the multidisciplinary cooperation, formed the Specialized Committee on Precision Therapy and Clinical Research of Lung Cancer of Guangdong Clinical Medical Association and acted as the chairman of the committee. Trained 4 master's students and 4 doctoral students, 2 of whom have published high-level papers (IF>10) as the first author; supervised 6 residents, 2 of whom have been awarded the National Natural Youth Foundation of China and 3 of whom have been awarded the post-doctoral program; supervised dozens of trainees, and trained talents for the establishment of the GCP organization in the sister hospitals; actively involved in the lectures for the large classes of undergraduates, and responsible for the clinical teaching of the department and the teaching work.

Precision treatment of advanced lung cancer, nasopharyngeal cancer

Clinical research of new anti-tumor drugs 

1993-1998, Kunming Medical College Clinical Medicine Major, Bachelor Degree;

2000-2003, First Affiliated Hospital of Sun Yat-Sen university, Master Degree;

2007-2011, Sun Yat-Sen University Cancer Center, PhD.

2016-2017, University of Texas MD Anderson Cancer Center, visiting scholar

Dr. Hong received his M.D. from Sun Yat-Sen University of Medical Sciences (SUMS) in 1984, and worked for the department of design, measure, and evaluation (DME), SUMS. During 1987 to 1988, he finished a postgraduate training on medical decision in Case Western Reserve University, Cleveland, USA . Since 1991, Dr. Hong turned to department of NPC, Cancer Center, SUMS, as a lecturer, and took part in a series of the clinical investigations using the theory of DME. The development of new clinical staging system of NPC (1992 NPC staging), which was used widely later in China, was one of Dr. Hong contributions. The proposition of the idea of stratified multiple modality therapy of NPC according to different clinical stages was another project of Dr. Hong using the methods and viewpoints of DME.

Dr. Hong was promoted to be an associate professor in 1994. The clinical trails of stratified comprehensive therapy of NPC in an ongoing project under the charge of Dr. Hong. His main interest is multiple modality combined therpay of NPC.

Prof. Sun Jian has been working in Sun Yat-sen University Cancer Center since 2001. From September 2012 to April 2013, he was engaged as an external reviewer of Center for Drug Evaluation (CDE) in China Food and Drug Administration (CFDA). Now he serves as team leader of Quality Control Team at the GCP Center (a qualified national institution for clinical trial of new drugs), engaged in clinical trials of new drugs, quality control of clinical trial of in-vitro diagnostic reagents and medical devices, and management of institution’s offices.

Dr. Ji-Bin Li received his bachelor and master's degree from Sun Yat-sen University, and his doctorate degree from the Chinese University of Hong Kong. He joined Sun Yat-sen University Cancer Center in 2016, and served as a biostatistician in the department of Clinical Research, and was appointed as an associate researcher in 2021. He mainly conducts research in biostatistics in clinical trials and longitudinal studies, clinical epidemiology, and behaviors, psychology and well-being. He has obtained several research grants (e.g., National Natural Science Foundation, Guangdong Natural Science Foundation) as a principle investigator. Dr. Ji-Bin Li's academic output includes an authored book and book chapters on biostatistics and clinical epidemiology, and over 80 academic papers in peer-reviewed journals.

Statistical methods in clinical trials; longitudinal study design and statistical methods; clinical epidemiology; behaviors, psychology and well-being, and quality of life.

2012-2016, PhD, The Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong

2009-2012, Master degree, School of Public Health, Sun Yat-sen University

2005-2009, Bachelor degree, Zhongshan school of Medicine, Sun Yat-sen University

1. Li JB, Zhang JX, Hong MH. Methodology for Clinical Research (2nd edition) [M]. Beijing: Science Press, 2025. (in Chinese)